BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Lyell Immunopharma\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Lyell Immunopharma\, Inc.'s drugs
  run\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05319314-10895@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20280630
DTEND;VALUE=DATE:20280701
SUMMARY:LYL273: Phase 1/2 readout est. (NCT05319314)
DESCRIPTION:LYL273\, phase 1/2.\nStudy: LYL273 for Patients With Relapsed o
 r Refractory mCRC\nEstimated primary completion: June 2028. This is a Clin
 icalTrials.gov estimate\, not a confirmed readout date\, and it can move.\
 nDrug page: https://assetmemo.bio/drug/lyl273#upcoming-events\nRegistry re
 cord: https://clinicaltrials.gov/study/NCT05319314
URL:https://assetmemo.bio/drug/lyl273#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05826535-10894@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Rondecabtagene autoleucel: Phase 1/2 readout est. (NCT05826535)
DESCRIPTION:Rondecabtagene autoleucel\, phase 1/2\, Large B-Cell Lymphoma.\
 nStudy: Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymp
 homa\nEstimated primary completion: 31 December 2028. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcoming-events
 \nRegistry record: https://clinicaltrials.gov/study/NCT05826535
URL:https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07188558-10894@assetmemo.bio
DTSTAMP:20261121T005634Z
DTSTART;VALUE=DATE:20291231
DTEND;VALUE=DATE:20300101
SUMMARY:Rondecabtagene autoleucel: Phase 3 readout est. (NCT07188558)
DESCRIPTION:Rondecabtagene autoleucel\, phase 3\, Large B-Cell Lymphoma.\nS
 tudy: A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 C
 AR T-Cell Therapy\nEstimated primary completion: December 2029. This is a 
 ClinicalTrials.gov estimate\, not a confirmed readout date\, and it can mo
 ve.\nDrug page: https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT07188558
URL:https://assetmemo.bio/drug/rondecabtagene-autoleucel#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
